MedTrace Logo

Trial Comparing hCG Triggering Versus hCG Associated With GnRH Agonist

NCT01607203 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2015-02-19

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to see whether patients triggered with only human Chorion Gonadotropin (hCG) have higher number of Metaphase II oocytes (MII) and implantation rate than patients triggered with hCG combined with Gonadotropin Releasing Hormone (GnRH) agonist.

Conditions

Interventions

DRUG

Decapeptyl Daily

Decapeptyl 0.2 mg SC once 1day

DRUG

pregnyl

5000 IU SC

Sponsors & Collaborators

  • Onze Lieve Vrouw Hospital

    collaborator OTHER

  • AZ Jan Palfijn Gent

    lead OTHER

Principal Investigators

  • Wim Decleer, gynacologist · IVF Centrum Jan Palfijn Gent

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Max Age
38 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-11-30
Primary Completion
2013-12-31
Completion
2013-12-31

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01607203 on ClinicalTrials.gov